Maze Therapeutics, a biopharmaceutical company, has commenced its Phase 1 clinical trial for MZE782, an oral small molecule therapy....

ONYDA XR (clonidine hydrochloride), a groundbreaking liquid non-stimulant ADHD medication, has been released for commercial availability in the United...

Merck has acquired CN201, a bispecific antibody, from Curon Biopharmaceutical. This acquisition strengthens Merck’s pipeline for treating B-cell malignancies...

Daiichi Sankyo and AstraZeneca‘s application for ENHERTU has been accepted for Priority Review by the US Food and Drug...

In the rapidly evolving landscape of health data regulation, the European Health Data Space (EHDS) initiative marks a transformative...

Fresenius Kabi, a subsidiary of Fresenius, and Formycon AG, a leading biosimilars developer, have received FDA approval for Otulfi™...

InCarda Therapeutics has demonstrated promising results in developing FlecIH-103, an inhaled solution for converting paroxysmal atrial fibrillation (PAF) to...

Purdue Pharma has completed the initial phase of a study investigating the use of nalmefene hydrochloride injection (HCl) in...

Precision BioSciences has submitted Clinical Trial Applications (CTAs) to initiate a Phase 1 study for its in vivo gene...

The U.S. FDA issued a draft guidance document, “Processes and Practices Applicable to Bioresearch Monitoring (BIMO) Inspections,” to streamline...